Published in Clin Vaccine Immunol on September 22, 2010
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Concern Serological evidence of Ebola virus infection in Indonesian orangutans. PLoS One (2012) 1.75
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Filovirus tropism: cellular molecules for viral entry. Front Microbiol (2012) 1.18
Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis (2011) 1.14
Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef (2011) 1.09
Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol (2013) 1.08
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03
Antibody-dependent enhancement of Marburg virus infection. J Infect Dis (2011) 1.02
Cathepsin B & L are not required for ebola virus replication. PLoS Negl Trop Dis (2012) 1.02
Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol (2012) 1.00
Discovery of an antibody for pan-ebolavirus therapy. Sci Rep (2016) 0.93
Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus. J Virol (2013) 0.92
Mapping of conserved and species-specific antibody epitopes on the Ebola virus nucleoprotein. Virus Res (2013) 0.92
Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron (2015) 0.91
Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis (2011) 0.91
C-type lectins do not act as functional receptors for filovirus entry into cells. Biochem Biophys Res Commun (2010) 0.90
Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One (2014) 0.87
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. J Infect Dis (2015) 0.82
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. J Infect Dis (2016) 0.81
Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species. J Infect Dis (2015) 0.81
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. J Infect Dis (2016) 0.80
Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis (2015) 0.79
Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Med Microbiol Immunol (2015) 0.79
Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice. PLoS One (2013) 0.79
Determination of specific antibody responses to the six species of ebola and marburg viruses by multiplexed protein microarrays. Clin Vaccine Immunol (2014) 0.78
Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses. J Infect Dis (2015) 0.76
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep (2016) 0.76
Development of an Immunochromatography Assay (QuickNavi-Ebola) to Detect Multiple Species of Ebolaviruses. J Infect Dis (2016) 0.75
Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. J Infect Dis (2015) 0.75
Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Crit Rev Microbiol (2017) 0.75
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol (2007) 168.76
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05
A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A (1997) 6.86
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol (1998) 5.16
Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 4.96
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol (2006) 4.01
Marburg virus infection detected in a common African bat. PLoS One (2007) 4.01
ELISA for the detection of antibodies to Ebola viruses. J Infect Dis (1999) 3.92
Discovery of swine as a host for the Reston ebolavirus. Science (2009) 3.68
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis (2009) 2.82
Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep (2001) 2.79
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog (2009) 2.29
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Antibody-dependent enhancement of Ebola virus infection. J Virol (2003) 1.62
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol (1992) 1.53
The pathogenesis of Ebola hemorrhagic fever. Trends Microbiol (2001) 1.49
Variation in the glycoprotein and VP35 genes of Marburg virus strains. Virology (1998) 1.45
Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins. J Clin Microbiol (2001) 1.39
Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine (2006) 1.38
Characterization of Marburg virus glycoprotein in viral entry. Virology (2006) 1.21
Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis (2007) 1.16
Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. J Gen Virol (1998) 1.01
Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus. Epidemiol Infect (2003) 1.00
Engineering N-glycosylation pathways in the baculovirus-insect cell system. Curr Opin Biotechnol (1998) 0.98
Analysis of linear B-cell epitopes of the nucleoprotein of ebola virus that distinguish ebola virus subtypes. Clin Diagn Lab Immunol (2003) 0.94
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis (2013) 4.92
Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (2006) 4.52
Characterization of H7N9 influenza A viruses isolated from humans. Nature (2013) 3.71
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis (2007) 3.47
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol (2006) 2.70
Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J Virol (2006) 2.60
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Pneumonia from human coronavirus in a macaque model. N Engl J Med (2013) 2.47
Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J Virol (2005) 2.45
Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A (2013) 2.29
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog (2009) 2.29
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
Polymorphisms and the differential antiviral activity of the chicken Mx gene. Genome Res (2002) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
The ecology of Ebola virus. Trends Microbiol (2007) 2.08
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol (2009) 2.05
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One (2013) 1.88
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol (2004) 1.80
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem (2005) 1.77
Concern Serological evidence of Ebola virus infection in Indonesian orangutans. PLoS One (2012) 1.75
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). Comp Med (2010) 1.71
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One (2010) 1.64
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005) 1.63
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis (2006) 1.62
Antibody-dependent enhancement of Ebola virus infection. J Virol (2003) 1.62
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol (2006) 1.61
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep (2013) 1.55
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Reston Ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis (2011) 1.54
The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis (2011) 1.53
A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol (2011) 1.53
Reverse genetics for crimean-congo hemorrhagic fever virus. J Virol (2003) 1.52
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis (2012) 1.51
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis (2012) 1.51
Animal models for Ebola and Marburg virus infections. Front Microbiol (2013) 1.51
Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol (2006) 1.49
Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol Cell Proteomics (2003) 1.49
Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology (2010) 1.48
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol (2005) 1.47